N is not to be trusted - I have been here for 3+ years so came out in profit - but it is clear that N is incapable of moving the trial forward
They had easiest trial - great technology - shortest trial one can have - still they could not raise sufficient funds to conduct trial for 50 patients independently - they actually have given the IP to Irish university as part of trial collaboration
Then they decided not to go with CE mark and failed in 505-b
During all this time - he was not giving clear information - Just ASAP
He represents the penny stock otc pinky biotech management who mislead investors and do not deliver results
That is part of the problem when you are dealing with the FDA on novel products, the researchers know a lot more than the reviewers do about the product, ie. something that is obvious to the researchers has to be spelled out phonetically to the reviewers....
News 
Market Data 
Discover 
